Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma

Part of paid clinical trials in Nashville, Tennessee.

Sponsor
Favrille
Study ID
NCT00258336
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • autologous immunoglobulin idiotype-KLH conjugate vaccine — BIOLOGICAL
  • rituximab — BIOLOGICAL
  • sargramostim — BIOLOGICAL

Study Details

RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Vaccines made from a person's cancer cells may help the body build an effective immune response to kill cancer cells. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood. Giving rituximab together with vaccine therapy and GM-CSF may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab together with vaccine therapy and GM-CSF works in treating patients with indolent B-cell non-Hodgkin's lymphoma.

Key Dates

First listed
Nov 24, 2005
Start date
Aug 31, 2004
Status verified
Aug 2008
Primary completion
Nov 30, 2009

Study Design

Enrollment
56 participants (estimated)
Primary purpose
TREATMENT

Primary Outcome Measure

Event-free survival by Kaplan-Meier

Locations (1)

FacilityCityStateZIPSite coordinators
Sarah Cannon Cancer Center at Centennial Medical CenterNashvilleTennessee37203
Clinical Trials Office - Sarah Cannon Cancer Center at Centenn
615-329-7274

Find similar trials in Nashville, TN

By research site
Sarah Cannon Cancer Center at Centennial Medical Center· Nashville, TN

Related Studies